Leadership | Precision for Medicine

Chad Clark

President and Chief Operating Officer, Precision Medicine Group

Recognized industry leader with deep expertise spanning biomarker-driven clinical development, patient access and global market access. In addition to the role at Precision Medicine Group, Chad is also President of Precision for Medicine. In prior roles he has served as Chief Operating Officer of United BioSource Corporation and founder of DataPhaseIV. Proven ability to scale operations in response to client needs, adding the end-to-end capabilities necessary to support development and patient access to today’s complex therapies.

Matt Arnold

President, Translational Sciences

Strategic, highly collaborative biotechnology industry veteran, driven by opportunities to bring life-changing therapeutics to patients. Over two decades of global, cross-functional biotech and pharmaceutical experience, across both rapid growth and mature organizations, including leadership positions at AVROBIO, AstraZeneca, and Amgen.

Sofia Baig

President, Clinical Solutions

Exceptional strategic leader, adept at driving organizational change and delivering top- and bottom-line business growth. Expert in strategic account management, global clinical development operations, and delivering transformational change inclusive of people, processes, and technology. Winner of multiple prestigious awards, including PharmaVoice 100 most inspiring leader in the life sciences industry, and as part of a team, the Catalyst Award for DEI work focused on improving women’s representation in senior leadership.

Steve Empoliti

Chief Commercial Officer

Visionary strategic leader, adept at propelling growth by strengthening relationships and enhancing capabilities to better meet customer needs. Driven by the desire to get advanced medicines to patients in need. Brings unique expertise from Fortune 100 companies, combining skills gleaned through commercial leadership, corporate strategy, client development, and global product management for major pharmaceutical companies, and more than a decade of management consulting to the life sciences industry.

Jake Graetz

Executive Vice President, Manufacturing Solutions

Industry leader focused on shaping corporate strategy and driving strategic initiatives for market-leading life sciences service providers. Skilled at identifying and pairing innovators to build cutting-edge integrated offerings. Outstanding track record of successfully steering cross-functional teams across a variety of critical operational initiatives.

John Khoury

Executive Vice President, Manufacturing Solutions

Long-standing biotech/pharmaceutical industry executive and global authority in cell and gene therapy facility builds. Key force in industrializing the world’s largest CGTx manufacturing footprint. Trusted strategic partner in make vs buy analysis, site and vendor selection, tech transfer execution strategies, and facility start-ups. Facilitated partnerships with 100+ life science organizations including startups, established biologics and CGTx innovators. Extensive experience with small and large molecules, including biologics and biosimilars. Dedicated champion for patient advocacy and philanthropy, who leads his team in contributing thousands of volunteer hours in support of patient-focused not-for-profit organizations.

Tony Khoury

Executive Vice President, Manufacturing Solutions

Life sciences leader who helped pioneer the industrialization of biologics and advanced therapies. Deep expertise in small and large molecules, honed through work with a range of life science organizations, from start-ups and academic centers to financial institutions and CMOs/CROs. Spearheaded significant global turnkey facility builds, automation, validation, engineering, and serialization track and trace, deploying billions in capital across the life sciences sector. Led the creation of the Advanced Therapy Manufacturing Playbook which has helped develop the world’s largest advanced therapy manufacturing footprint. Actively serves on multiple boards including academic, philanthropic, biotech, and financial investment institutions.

Anshul Mangal

President, Manufacturing Solutions

Groundbreaking biotech entrepreneur, executive, and investor, dedicated to delivering transformative treatments to the patients who need them. Pioneered the industrialization of advanced therapeutics, including some of the earliest commercially approved cell and gene therapies, radioligand treatments, RNA-based therapies, and cutting-edge biologics. Created the leading global biologics and advanced therapy engineering consulting firm and developed the largest cell and gene therapy manufacturing footprint in the world. Deeply committed to advancing next-generation medicines, serves on multiple boards, philanthropic organizations, and patient-advocacy groups, including IQHQ, Alliance for Regenerative Medicines, and Alliance for mRNA Medicines.

Scott Marshall, PhD

President, QuartzBio

Industry authority on precision medicine-guided strategy and development, particularly in translational informatics, data science, and software development operations. Pioneer in SaaS management of complex streams of associated biomarker data and clinical sample inventories. Strategist across a variety of data-centric spaces, including development of complex biomarker signatures for use in patient selection.

Deborah Phippard, PhD

Chief Scientific Officer

Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy.

Harpreet Singh, MD

Chief Medical Officer

Industry-leading oncologist and demonstrated medical leader in precision medicine, novel trial design and innovative regulatory initiatives designed to expedite drug approvals. Draws on nearly a decade leading oncology and rare disease programs at the FDA. Former fellow at the National Cancer Institute and frequent featured speaker at ASCO and AACR. CDER technical authority on oncologic drug and biological products for thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors and rare tumors.

Sofia Baig

President

Exceptional strategic leader, adept at driving organizational change and delivering top- and bottom-line business growth. Expert in strategic account management, global clinical development operations, and delivering transformational change inclusive of people, processes, and technology. Winner of multiple prestigious awards, including PharmaVoice 100 most inspiring leader in the life sciences industry, and as part of a team, the Catalyst Award for DEI work focused on improving women’s representation in senior leadership.

Harpreet Singh, MD

Chief Medical Officer

Industry-leading oncologist and demonstrated medical leader in precision medicine, novel trial design and innovative regulatory initiatives designed to expedite drug approvals. Draws on nearly a decade leading oncology and rare disease programs at the FDA. Former fellow at the National Cancer Institute and frequent featured speaker at ASCO and AACR. CDER technical authority on oncologic drug and biological products for thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors and rare tumors.

Nithiya Ananthakrishnan

Senior Vice President, Biometrics

Visionary executive with a distinguished track-record fostering an environment of continuous innovation and growth through people-centric strategies. Data sciences leader focused on data analysis, visualization, and solutions to solve key issues in clinical trials. On a personal level, deeply committed to supporting educational excellence, particularly for underprivileged children.

Andrea Cotton-Berry

Global Head of Strategic Development

Notable authority in global operations, dedicated to fostering team spirit of excellence and collaboration with internal and external partners. Veteran of the quest to improve oncology therapies and extend lives, including 15+ years in oncology drug development, building on 10 years in obstetrics and women’s health.

Simon Fleming

Executive Vice President

Veteran of the pharmaceutical industry, fluent in all aspects of clinical trial management, including business development, strategic operations, process improvement, technology implementation and finance. Special focus on global quality management, data management, biostatistics and statistical programming operations.

Carolyn Harley

Head Operational Excellence

Seasoned industry veteran focused on maximizing operational quality and efficiency across clinical research through people, process, and technology. Leads technical and process support for clinical systems, ensures strategic resource management, develops preferred provider relationships, and manages vendor governance activities.

Katie McGuire

Senior Vice President, Regulatory and Site Start-Up

Seasoned pharma leader with extensive expertise in oncology drug development and early phase clinical development. Veteran across multiple therapeutic indications in a wide range of multi-country, full-service studies through every phase. Strong communicator and trained executive coach who thrives on change and excels under pressure.

Sallyanne Williams

Senior Vice President, Global Head Project Management

Long-standing project management leader dedicated to improving delivery across all phases of product development. Working on a global scale, applies strategic smarts to operational delivery and financial management. Recognized as one of the PharmaVoice 100, some of the industry’s most inspiring people, awarded in the “Change Agent” category.